(Total Views: 430)
Posted On: 07/27/2020 1:54:02 PM
Post# of 36568
Here’s where the water gets muddy for me and a perfect example of why I think GNBT and NGIO should not share the same CEO.
NGIO is developing the vaccine. The FDA letter clearly states that they received NGIOs request for written response.
So why is this a GNBT 8K? This should be on NHIO letterhead. It should be an NGIO filing.
If GNBT wants to PR it it should say “GNBT Subsidiary NGIO Receives FDA Response”
This is sloppily worded as a GNBT PR. Why is that?
NGIO is developing the vaccine. The FDA letter clearly states that they received NGIOs request for written response.
So why is this a GNBT 8K? This should be on NHIO letterhead. It should be an NGIO filing.
If GNBT wants to PR it it should say “GNBT Subsidiary NGIO Receives FDA Response”
This is sloppily worded as a GNBT PR. Why is that?
(3)
(0)
